Table 5. Univariate and multivariate analysis of prognostic factors for disease-free survival in 50 HCC patients after living donor liver transplantation.
| Factors | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Recipient age | 0.99 (0.92–1.05) | 0.680 | – | – | |
| Recipient BMI >25 kg/m2 | 0.52 (0.15–1.83) | 0.310 | – | – | |
| Progressive hyperbilirubinemia | 1.45 (0.19–10.97) | 0.720 | – | – | |
| Refractory ascites | 0.36 (0.05–2.71) | 0.320 | – | – | |
| MELD score >20 | 1.45 (0.19–10.97) | 0.720 | – | – | |
| Child-Pugh classification C | 3.13 (0.88–11.11) | 0.076 | 2.22 (0.76–6.51) | 0.145 | |
| Portal vein thrombosis | 0.46 (0.06–3.49) | 0.455 | – | – | |
| Pretransplant infection | 0.84 (0.11–6.36) | 0.868 | – | – | |
| Sarcopenia | 2.87 (1.06–7.80) | 0.038 | 2.60 (0.95–7.10) | 0.062 | |
| Pre-transplant hospital Stay | 1.10 (0.42–2.91) | 0.842 | – | – | |
| Operative time >10 hours | 0.55 (0.18–1.64) | 0.282 | – | – | |
| Meeting Milan criteria | 0.31 (0.11–0.89) | 0.030 | 0.34 (0.12–0.98) | 0.046 | |
| Tumor size | 1.15 (1.03–1.30) | 0.017 | – | – | |
| Tumor number | 1.14 (0.98–1.33) | 0.082 | – | – | |
| AFP >400 ng/mL | 1.76 (0.68–4.58) | 0.245 | – | – | |
| Donor BMI | 0.92 (0.77–1.09) | 0.332 | – | – | |
| GRWR >0.8% | 1.29 (0.48–3.50) | 0.610 | – | – | |
| ABO-incompatible | 1.05 (0.37–2.98) | 0.932 | – | – | |
| Biological related donor | 2.22 (0.77–6.38) | 0.140 | – | – | |
HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; BMI, body mass index; MELD, model for end-stage liver disease score; AFP, alpha fetoprotein; GRWR, graft-to-recipient weight ratio; HR, hazard ratio.